Intérêt actuel des selective progesterone receptor modulators (SPRM) dans l’endométriose

Die medikamentöse Therapie der Patientin mit Endometriose

“…Der SPRM Ulipristalacetat ist erfolgreich als Notfallkontrazeptivum und bei der medikamentösen Behandlung von Uterusmyomen. Es wird vermutet, dass Ulipristalacetat auch eine Therapieoption bei der Behandlung der Endometriose sein könnte [71]. Daten stehen aktuell jedoch aus.…”

Novel agents for the medical treatment of endometriosis

“…The nuclear progesterone receptor is activated after interaction with its ligand and activates or inhibits the transcription depending on the ligand and tissuelocation [15]. PRC can be found in the uterus during pregnancy and in breast cancer cells.…”

“…SPRM inhibits the production of prostaglandins and hence reduces COX-2 levels [15]. Onapristone is a complete antagonist, whereas mifepristone and asoprisnil have mixed effects.…”

“…Given that asoprisnil and onapristone were withdrawn because of endometrial side-effects and/or severe hepatic toxicity [15], the potential value of mifepristone, telapristone and ulipristal acetate remains to be established with respect to safety and efficacy in the treatment of endometriosis related pain.…”

An exceptional case of degenerative endometriosis of the uterine torus

“…Endometriosis affects 10%–15% of the female population of childbearing age and 20%–50% of infertile women. 1 Malignant transformation in endometriotic lesions is a rare event (1%), 2 , 3 most often described in cases of external endometriosis, in particular ovarian endometriosis 4 , 5 and more rarely in cases of deep infiltrating endometriosis (DIE). DIE is defined by infiltration of the peritoneum ≥5 mm or invasion of the bowel, ureter, or bladder by endometriotic lesions.…”